## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

## LISTING OF CLAIMS

- 1-14. Canceled
- 15. (Previously presented) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.
  - 16. (Canceled)
- 17. (Original) The method of Claim 15, wherein said polypeptide is fused to an Fc region of an immunoglobulin.
- 18. (Previously presented) The method of Claim 15, wherein said polypeptide comprises a Thanatos (death) associated protein (THAP) dimerization domain.
- 19. (Previously presented) The method of Claim 18, wherein said Thanatos (death) associated protein (THAP) dimerization domain interacts with one or more THAP dimerization domains to form a THAP oligomer.
- 20. (Original) The method of Claim 15, wherein said polypeptide is a recombinant polypeptide.
  - 21. (Canceled)
- 22. (Previously presented) The method of Claim 15, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.
  - 23. (Canceled)
- 24. (Previously presented) The method of Claim 15, wherein said polypeptide is SEQ ID NO: 3.
  - 25. (Canceled)

- 26. (Previously presented) The method of Claim 15, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
- 27. (Previously presented) The method of Claim 26, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

28-91. (Canceled)

- 92. (Previously presented) The method of Claim 15, wherein said polypeptide comprises an isolated polypeptide.
  - 93. (Canceled)
- 94. (Previously presented) The method of Claim 92, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.
- 95. (Previously presented) The method of Claim 92, wherein said polypeptide is SEQ ID NO: 3.
  - 96. (Canceled)
- 97. (Previously presented) The method of Claim 92, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
  - 98. (Canceled)
- 99. (Previously presented) The method of Claim 15, wherein said polypeptide binds to CCL5.
- 100. (Previously presented) The method of Claim 92, wherein said polypeptide binds to CCL5.
- 101. (Previously presented) A method of binding a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3, wherein the chemokine is bound.
- 102. (Previously presented) The method of Claim 101, wherein said polypeptide is fused to an Fc region of an immunoglobulin.
- 103. (Previously presented) The method of Claim 101, wherein said polypeptide comprises a Thanatos (death) associated protein (THAP) dimerization domain.

- 104. (Previously presented) The method of Claim 103, wherein said THAP dimerization domain interacts with one or more Thanatos (death) associated protein (THAP) dimerization domains to form a THAP oligomer.
- 105. (Previously presented) The method of Claim 101, wherein said polypeptide is a recombinant polypeptide.
  - 106. (Canceled)
- 107. (Previously presented) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.
- 108. (Previously presented) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.
  - 109. (Canceled)
- 110. (Previously presented) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
- 111. (Previously presented) The method of Claim 110, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.
  - 112. (Canceled)
- 113. (Previously presented) The method of Claim 101, wherein said polypeptide comprises an isolated polypeptide.
  - 114. (Canceled)
- 115. (Previously presented) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.
- 116. (Previously presented) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.
  - 117. (Canceled)
- 118. (Previously presented) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
  - 119. (Canceled)

- 120. (Previously presented) The method of Claim 101, wherein said polypeptide binds CCL5.
- 121. (Previously presented) The method of Claim 113, wherein said polypeptide binds CCL5.
- 122. (New) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.
- 123. (New) The method of claim 122, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3.
- 124. (New) The method of claim 122, wherein polypeptide is selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 125. (New) The method of claim 122, wherein said polypeptide is SEQ ID NO: 3.
- 126. (New) The method of claim 122, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.
- 127. (New) The method of claim 122, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
- 128. (New) The method of claim 127, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.
- 129. (New) The method of claim 122, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 130. (New) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least

95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

- 131. (New) The method of claim 130, wherein said chemokine is selected from the group consisting of SLC, CCL19 and CCL5.
- 132. (New) The method of claim 130, wherein said chemokine is selected from the group consisting of CXCL9 and CXCL10.
  - 133. (New) The method of claim 130, wherein said chemokine is SLC.
  - 134. (New) The method of claim 130, wherein said chemokine is CC19.
  - 135. (New) The method of claim 130, wherein said chemokine is CC5.
  - 136. (New) The method of claim 130, wherein said chemokine is CXCL9.
  - 137. (New) The method of claim 130, wherein said chemokine is CXCL10.
- 138. (New) The method of claim 130, wherein said polypeptide selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.
- 139. (New) The method of claim 130, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.
- 140. (New) The method of claim 130, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 141. (New) The method of claim 140, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.
- 142. (New) A method of binding a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein said chemokine is bound.
- 143. (New) The method of claim 142, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3.

- 144. (New) The method of claim 142, wherein polypeptide is selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 145. (New) The method of claim 142, wherein said polypeptide is SEQ ID NO: 3.
- 146. (New) The method of claim 142, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.
- 147. (New) The method of claim 142, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.
- 148. (New) The method of claim 147, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.
- 149. (New) The method of claim 142, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 150. (New) A method of binding a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein said chemokine is bound.
- 151. (New) The method of claim 150, wherein said chemokine is selected from the group consisting of SLC, CCL19 and CCL5.
- 152. (New) The method of claim 150, wherein said chemokine is selected from the group consisting of CXCL9 and CXCL10.
  - 153. (New) The method of claim 150, wherein said chemokine is SLC.
  - 154. (New) The method of claim 150, wherein said chemokine is CC19.
  - 155. (New) The method of claim 150, wherein said chemokine is CC5.
  - 156. (New) The method of claim 150, wherein said chemokine is CXCL9.
  - 157. (New) The method of claim 150, wherein said chemokine is CXCL10.

- 158. (New) The method of claim 150, wherein said polypeptide selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.
- 159. (New) The method of claim 150, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.
- 160. (New) The method of claim 150, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.
- 161. (New) The method of claim 160, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.